Biogen Exercises Exclusive Worldwide Option to Develop & Commercialize Ionis’s BIIB067 (IONIS-SOD1RX) for Amyotrophic Lateral Sclerosis (ALS)

 Biogen Exercises Exclusive Worldwide Option to Develop & Commercialize Ionis’s BIIB067 (IONIS-SOD1RX) for Amyotrophic Lateral Sclerosis (ALS)

Biogen Exercises Exclusive Worldwide Option to Develop & Commercialize Ionis’s BIIB067 (IONIS-SOD1RX) for Amyotrophic Lateral Sclerosis (ALS)

Shots:

  • Ionis to receive $35M upfront, $55M as future milestones and royalties on net sales. Biogen to get worldwide development and commercialization rights and will be responsible for cost of further development and manufacturing
  • The option to license is exercised, based on P-I study (N=70) of BIIB067 vs PBO, demonstrating lowering of SOD1 protein levels in CSF and proved to be safe and well-tolerated
  • BIIB067 is an antisense oligonucleotide (ASO) RNase H-mediated inhibitor of SOD1 Mrna, targeted to treat ALS with SOD1 mutations

Click here to read full press release/ article | Ref: Biogen | Image:The Street

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post